BETAJECT DIN 02237835
Health Canada record
| Active ingredient(s) | BETAMETHASONE ACETATE 3 MG; BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 3 MG |
|---|---|
| Dosage form | Suspension |
| Route | Intramuscular; Intralesional; Intra-Articular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H02AB01 BETAMETHASONE |
| Original market date | 02-Jul-1998 |
| Current status date | 01-Aug-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BETAMETHASONE ACETATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00028096 | CELESTONE SOLUSPAN | ORGANON CANADA INC. | Suspension | BETAMETHASONE ACETATE 3 MG; BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) 3 MG | Marketed |
| 02556529 | DUOTIC | DECHRA LTD | Gel | BETAMETHASONE ACETATE 1 MG; TERBINAFINE 10 MG | Marketed |
| 02438534 | OSURNIA | DECHRA LTD | Gel | BETAMETHASONE ACETATE 1 MG; FLORFENICOL 10 MG; TERBINAFINE 10 MG | Marketed |
International API supply for BETAMETHASONE ACETATE
4 active FDA Drug Master Files.
Request a quote for BETAJECT